1 Clinical Subphenotypes of Multisystem Inflammatory Syndrome in Children: An EHR-2 based cohort study from the RECOVER program

- 3
- 4 Authors: Suchitra Rao, MBBS^{1*}, Naimin Jing, PhD^{2*}, Xiaokang Liu, PhD², Vitaly Lorman, PhD³,
- 5 Mitchell Maltenfort, PhD³, Julia Schuchard, PhD³, Qiong Wu, PhD², Jiayi Tong, MS², Hanieh
- 6 Razzaghi, MPH^{3,} Asuncion Mejias, MD⁴, Grace M. Lee, MD⁵; Nathan M. Pajor, MD⁶, Grant S.
- 7 Schulert, MD⁷, Deepika Thacker, MD⁸, Ravi Jhaveri⁹, MD, Dimitri A. Christakis, MD¹⁰, L. Charles
- 8 Bailey, MD^{3,11}, Christopher B. Forrest, MD^{3,11}, Yong Chen, PhD² on behalf of the RECOVER
- 9 consortium
- 10 *SR and NJ contributed to the manuscript equally

11 Affiliations:

- ¹Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital
- 13 Colorado, Aurora, CO
- ²Department of Biostatistics, Epidemiology and Informatics, the Perelman School of Medicine,
- 15 University of Pennsylvania, Pennsylvania, PA
- ¹⁶ ³Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA
- ⁴Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital and
- 18 The Ohio State University, Columbus, OH
- ⁵Department of Pediatrics (Infectious Diseases), Stanford University School of Medicine,
- 20 Stanford, CA
- ⁶Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and University
- 22 of Cincinnati College of Medicine, Cincinnati, OH

- 23 ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of
- 24 Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
- ²⁵ ⁸Division of Cardiology, Nemours Children's Health, Wilmington, DE
- ⁹Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago,
- 27 IL
- ¹⁰Center for Child Health, Behavior and Development, Seattle Children's Hospital, Seattle, WA
- ¹¹Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania,
- 30 Philadelphia, PA
- 31 Corresponding Author:
- 32 Suchitra Rao, MBBS, MSCS
- 33 Associate Professor of Pediatrics (Infectious Diseases/Hospital Medicine/Epidemiology),
- 34 University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO
- 35 13123 E 16th Ave Box 090
- 36 Aurora, CO 80045
- 37 Email: suchitra.rao@childrenscolorado.org
- 38 **Co-Corresponding Author:**
- 39 Yong Chen, Ph.D.
- 40 Professor of Biostatistics
- 41 Perelman School of Medicine, University of Pennsylvania
- 42 423 Guardian Dr, Blockley Hall 602, Philadelphia, PA 19104
- 43 Email: ychen123@pennmedicine.upenn.edu

- 44 **Abbreviated Title**: MIS-C Subphenotypes
- 45 **Funding Source:** This research was funded by the National Institutes of Health (NIH)
- 46 Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery
- 47 (RECOVER) program of research.
- 48 **Disclaimer:** The views and conclusions contained in this document are those of the authors
- 49 and should not be interpreted as representing the official policies, either expressed or implied, of
- 50 the NIH.
- 51 **Key Words:** Multisystem inflammatory syndrome in children, PEDSnet, post-acute sequelae
- 52 COVID, latent class analyses
- 53 Abbreviations: LCA-- latent class analyses; MIS-C- multisystem inflammatory syndrome in
- children; PASC--post-acute sequelae of SARS-CoV-2 infection; COVID-19--coronavirus disease
- 55 2019; SARS-CoV-2--severe acute respiratory syndrome coronavirus 2; PCR--polymerase chain
- reaction; EHR--electronic health record; ED--emergency department; UC--urgent care; ICU-
- 57 intensive care unit; CI--confidence intervals; ICD-10--International Classification of Diseases,
- version 10; PMCA-- Pediatric Medical Complexity Algorithm
- 59 Word Count: 2492
- 60

61 **Research in context**

62 Evidence before this study

63 We searched PubMed and preprint articles from December 2019, to July 2022, for studies published in English that investigated the clinical subphenotypes of MIS-C using 64 the terms "multi-system inflammatory syndrome in children" or "pediatric inflammatory" 65 multisystem syndrome" and "phenotypes". Most previous research described the 66 symptoms, clinical characteristics and risk factors associated with MIS-C and how these 67 differ from acute COVID-19, Kawasaki Disease and Toxic Shock Syndrome. One 68 single-center study of 63 patients conducted in 2020 divided patients into Kawasaki and 69 70 non-Kawasaki disease subphenotypes. Another CDC study evaluated 3 subclasses of MIS-C in 570 children, with one class representing the highest number of organ 71 systems, a second class with predominant respiratory system involvement, and a third 72 class with features overlapping with Kawasaki Disease. However, this study evaluated 73 74 cases from March to July 2020, during the early phase of the pandemic when misclassification of cases as Kawasaki disease or acute COVID-19 may have occurred. 75 Therefore, it is not known from the existing literature whether the presentation of MIS-C 76 77 has changed with newer variants such as delta and omicron.

78 Added value of this study

PEDSnet provides one of the largest MIS-C cohorts described so far, providing sufficient power for detailed analyses on MIS-C subphenotypes. Our analyses span the entire length of the pandemic, including the more recent omicron wave, and provide an update on the presentations of MIS-C and its temporal dynamics. We found that children have a spectrum of illness that can be characterized as mild (lower

- 84 inflammatory markers, fewer organ systems involved), moderate (4-6 organ involvement
- 85 with clinical overlap with acute COVID-19) and severe (higher inflammatory markers,
- critically ill, more likely to have cardiac involvement, with hypotension/shock and need
- 87 for vasopressors).

88 Implications of all the available evidence

- 89 These results provide an update to the subphenotypes of MIS-C including the more
- 90 recent delta and omicron periods and aid in the understanding of the various
- 91 presentations of MIS-C. These and other findings provide a useful framework for clinicians
- 92 in the recognition of MIS-C, identify factors associated with children at risk for increased
- 93 severity, including the importance of laboratory parameters, for risk stratification, and to
- 94 facilitate early evaluation, diagnosis and treatment.

96 Abstract:

Background: Multi-system inflammatory syndrome in children (MIS-C) represents one of the
most severe post-acute sequelae of SARS-CoV-2 infection in children, and there is a critical
need to characterize its disease patterns for improved recognition and management. Our
objective was to characterize subphenotypes of MIS-C based on presentation, demographics
and laboratory parameters.

Methods: We conducted a retrospective cohort study of children with MIS-C from March 1, 2020 - April 30, 2022 and cared for in 8 pediatric medical centers that participate in PEDSnet. We included demographics, symptoms, conditions, laboratory values, medications and outcomes (ICU admission, death), and grouped variables into eight categories according to organ system involvement. We used a heterogeneity-adaptive latent class analysis model to identify three clinically-relevant subphenotypes. We further characterized the sociodemographic and clinical characteristics of each subphenotype, and evaluated their temporal patterns.

109 Findings: We identified 1186 children hospitalized with MIS-C. The highest proportion of 110 children (44.4%) were aged between 5-11 years, with a male predominance (61.0%), and non-111 Hispanic white ethnicity (40.2%). Most (67.8%) children did not have a chronic condition. Class 1 represented children with a severe clinical phenotype, with 72.5% admitted to the ICU, higher 112 inflammatory markers, hypotension/shock/dehydration, cardiac involvement, acute kidney injury 113 and respiratory involvement. Class 2 represented a moderate presentation, with 4-6 organ 114 systems involved, and some overlapping features with acute COVID-19. Class 3 represented a 115 116 mild presentation, with fewer organ systems involved, lower CRP, troponin values and less cardiac involvement. Class 1 initially represented 51.1% of children early in the pandemic, 117 118 which decreased to 33.9% from the pre-delta period to the omicron period.

- 119 Interpretation: MIS-C has a spectrum of clinical severity, with degree of laboratory
- abnormalities rather than the number of organ systems involved providing more useful
- 121 indicators of severity. The proportion of severe/critical MIS-C decreased over time.

123 Introduction

In April 2020, cases of a novel hyperinflammatory disorder associated with SARS-CoV-2 124 125 infection were first reported in the UK and Italy,^{1,2} which was subsequently termed multisystem inflammatory syndrome in children (MIS-C). The Centers for Disease Control and Prevention 126 127 (CDC) defines cases as individuals younger than 21 years of age presenting with fever. 128 laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with involvement of greater than or equal to 2 organs, with no alternative 129 plausible diagnoses and a positive SARS-CoV-2 test (PCR, serology, antigen) or COVID-19 130 exposure within the preceding 4 weeks.³ Reports indicate that most children are 6-12 years of 131 age, of Black/African American race or Hispanic ethnicity, and obesity was the most common 132 pre-existing condition.⁴⁻⁶ MIS-C is one of the most severe post-acute sequelae of SARS-CoV-2 133 infection in children, and as of June 2022, the CDC has reported 8.639 cases of MIS-C; 70 134 135 children have died due to associated complications.⁷

136 Children with MIS-C can present with a highly heterogeneous spectrum of clinical features, making the diagnosis challenging. The clinical presentation can overlap with features of 137 138 Kawasaki disease, acute COVID-19, toxic shock, and macrophage activation syndrome. Common features include fever, gastrointestinal symptoms (including abdominal pain and 139 diarrhea), cardiac complications (myocarditis and coronary artery dilatation), mucocutaneous 140 findings (rash, mucositis) and respiratory symptoms.⁸ Given the wide spectrum of clinical 141 142 presentations of this novel condition, there is a need to further characterize its disease patterns, 143 which will ultimately improve outcomes. Further elucidation of MIS-C subphenotypes can help 144 identify children at greatest risk of severe outcomes, and determine which subgroups may benefit from more targeted therapies. Therefore, the objectives of this study were to define 145 146 subphenotypes of MIS-C based on symptoms, diagnoses and laboratory parameters.

147 Methods

148 Data Source

- 149 This retrospective cohort study is part of the NIH Researching COVID to Enhance Recovery
- 150 (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute sequelae of
- 151 SARS-CoV-2 infection (PASC). For more information on RECOVER, visit
- 152 <u>https://recovercovid.org/</u>. The original study cohort has been described elsewhere.⁹ We
- used electronic health record (EHR) data from PEDSnet member institutions.^{10,11} Participating
- institutions included Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical
- 155 Center, Children's Hospital Colorado, Ann & Robert H. Lurie Children's Hospital of Chicago,
- 156 Nationwide Children's Hospital, Nemours Children's Health System (a Delaware and Florida
- 157 health system), Seattle Children's Hospital, and Stanford Children's Health. We retrieved EHR
- data from all healthcare encounters among hospitalized children and adolescents < 21 years of
- age who were diagnosed with MIS-C from March 1, 2020 to April 30, 2022. Data were extracted
- 160 from the PEDSnet COVID-19 Database-Version 2022-05-19, which included EHR data with
- 161 dates of service up to April 30, 2022. Cohort entry was defined as the 1 day before the first
- 162 hospitalization associated with an MIS-C diagnosis term (index hospitalization). We combined
- 163 hospitalizations if the discharge date of the first hospitalization was within 24 hours of the
- subsequent hospitalization admission date. We excluded one patient with missing admission or
- discharge dates. The Children's Hospital of Philadelphia's Institutional Review Board designated
 this study as not human subjects' research and waived informed consent.
- 167 Variables
- We included the following indicator variables: demographics, diagnoses (including symptoms
 and conditions), medications, laboratory values and clinical outcomes (ICU, mechanical
- 170 ventilation, death), which were coded dichotomously and later grouped to form variables used in

our analysis. The indicator variable was included in the analyses if at least one occurrence was
recorded in the EHR from 1 day prior through the entire duration of hospitalization. In addition,
age, number of days during hospitalization, number of days in ICU, and laboratory test results
were included as continuous or categorical variables.

175 Statistical Analyses

176 First, we grouped highly-correlated indicator variables, including diagnoses (symptoms and 177 conditions) and laboratory values, into eight broader categories according to their organ system involvement, which were cardiac, gastrointestinal, hematological, neurologic, renal, respiratory, 178 179 dermatologic and shock (See eTable 1 for definitions of each variable). The variable for a 180 particular organ system was defined based on the occurrence of any symptom, condition, laboratory value, or procedure type related to that system. We further divided the cardiac 181 182 system into three categories: coronary artery abnormalities only, myocardial dysfunction with no coronary artery abnormalities, and coronary artery abnormalities and myocardial dysfunction. 183 184 Secondly, with the ten manifest variables defined over the eight broad organ systems, we applied a latent class analysis (LCA) model in which an Expectation-Maximization (EM) 185 algorithm was used for estimation.^{12,13} To account for heterogeneity across hospitals yet 186 187 ensuring unified definitions of subphenotypes, we assumed the same collection of 188 subphenotypes but potentially different mixing proportions of each of the subphenotypes across the health systems. Such generalization of the traditional LCA model is necessary because the 189 prevalence of subphenotypes can be substantially different due to different distributions of age, 190 191 race/ethnicity, and referral patterns which can be strongly associated with the presentation of 192 MIS-C.

For sensitivity analysis, we fitted LCA to the ten manifest variables under different assumed
 numbers of latent classes, varying from two to six. Log-likelihood, Bayesian Information

Criterion (BIC), and clinical adjudication among our clinician work group were incorporated toselect the appropriate number of clinical-relevant latent classes.

197 For identification of identified latent classes (subphenotypes), proportions of the ten manifest 198 variables over the eight broad organ systems across latent classes were displayed as heatmaps 199 of prevalence. To further characterize these identified latent classes, distributions of clinical 200 indicator variables, including demographic characteristics, and individual symptoms, conditions, laboratory results, procedures, and medications, were displayed across the latent classes also 201 202 using heatmaps of prevalence. To characterize the differences in each continuous clinical 203 variable across latent classes, sample mean, standard error, median and interquartile range were calculated and summarized. To reduce the impact of misclassifications of latent classes, 204 205 instead of using classification based on maximum posterior probability, all calculations of the 206 characterizations were based on weighted prevalence with weights being the posterior 207 probabilities. The results are presented using heatmaps and forest plots.

To evaluate potential time-varying effects, we also evaluated the changes of the proportions for each subphenotype over time in 3-month periods. Within each time period, the proportions of subphenotypes were calculated using posterior class membership probabilities. The change in subclass proportions over time was shown as a line graph in Figure 4. In addition, the change in the prevalence of the ten variables for each of the latent classes over time was estimated.

To further examine the validity of our LCA approach, we applied the subphenotypes of MIS-C to a cohort of children testing positive for COVID-19 by PCR without an MIS-C diagnosis.⁹ We constructed latent classes for SARS-CoV-2 positive patients, with an evaluation period of -7 to 28 days from the test date to evaluate our construct validity. We applied the model with three latent classes to the ten variables as used in the MIS-C analysis and identified three subphenotypes of COVID-19. We compared the characteristics of MIS-C and COVID-19 subphenotypes and visualized the distance among them measured by fixation index using

multidimensional scaling. Analyses were conducted using R version 4.1.2 (2021-11-01). The
 package used for LCA was poLCA 1.4.1 (2014-01-10).^{14,15}

222 Results

Among 1,853,557 children in the PEDSnet cohort who received a COVID-19 diagnosis or 223 224 vaccination, had a COVID-19 test (PCR, serology or antigen), or demonstrated evidence of 225 respiratory illness or post-acute sequelae of SARS-CoV-2 and had a visit at any of the eight 226 PEDSnet sites between March 2020 and April 2022, we identified 1186 children who were 227 hospitalized with MIS-C (eFigure 1). A description of the study cohort is provided in Table 1. 228 The highest proportion of children (44%) were aged between 5-11 years, with a male 229 predominance (61%), and non-Hispanic White ethnicity (40.2%). Most (67.8%) children did not have any chronic conditions as defined by the Pediatric Medical Complexity Algorithm (PMCA). 230 ¹⁶ In our MIS-C cohort, 40.5% were admitted to the ICU, 15.2% required mechanical ventilation 231 (invasive and non-invasive), and 11 (0.92%) children died. 232

233 Latent Class analyses identified three subphenotypes (Figure 1), with the patient demographics of each class summarized in Figure 2 and eFigure 2. The overall proportions of Class 1, 2, and 234 3 were 40.0%, 24.0%, and 36.0%, respectively. The race and ethnicity of children were similar 235 236 in each class, with the exception of a higher proportion of children of black/African American 237 race in Class 1. A higher proportion of children 12 years of age and older, and those with a complex chronic condition were identified in Class 1. The proportion of each class by PEDSnet 238 site is shown in eTable 2, with some observed heterogeneity. Figure 3 and eFigure 3 and 239 display specific diagnoses, laboratory results and medications in each group. Class 1 240 241 represented children with a more severe clinical phenotype, with 72.5% admitted to the ICU. with a longer mean inpatient stay and longer ICU length of stay. Children in Class 1 had a 242 higher prevalence of cardiac involvement, with abnormal troponin levels, hypotension and 243 shock/dehydration, need for vasopressors and fluid resuscitation. This class was more likely to 244

245 have abnormal laboratory findings including lymphopenia, elevated d-dimer and thrombocytopenia. There was a higher prevalence of acute kidney injury, and respiratory 246 247 involvement (respiratory failure, pleural effusion, need for ventilation). Children in Class 1 had 248 the highest usage of systemic steroids among all classes. Class 2 represented a group with a 249 moderate presentation, with similar multiple organ system involvement to Class 3, including 250 dermatologic (rashes), gastrointestinal (abdominal pain, nausea and vomiting), hematologic abnormalities (lymphopenia, thrombocytopenia, elevated d-dimer), renal (fluid and electrolyte) 251 252 and respiratory (cardiorespiratory signs and symptoms), with a heat map pattern similar to acute 253 COVID-19 (eFigure 4) and 2-dimensional plot demonstrating close proximity between MIS-C Class 2 and COVID-19 Class 1 (eFigure 5). This group had the highest use of non-steroidal 254 anti-inflammatory and antirheumatic medications. Class 3 represented a mild population, with 255 fewer systems involved, and laboratory values demonstrating fluid and electrolyte disturbance, 256 257 lymphopenia, thrombocytopenia, and elevated d-dimer. The proportions of each subphenotype over time are shown in Figure 4. A higher proportion of children had the more severe MIS-C 258 presentation in the earlier phase of the pandemic (Class 1 represented 51.1% of children from 259 March 2020 to August 2020), which decreased over time (Class 1 represented 33.9% of 260 261 children from January to April, 2022). eFigure 6 shows the prevalence of organ system 262 involvement for all patients with MIS-C over time, demonstrating significant declines over time in cardiac, hematological, respiratory involvement, and shock. 263

264 Discussion

In our multicenter cohort of 1,186 children hospitalized with MIS-C, we identified 3 latent classes
with different illness characteristics. Class 1 represented critically ill patients, with a higher
proportion of children being of older age, black/African American race, with underlying medical
complexity, presenting with hypotension/shock, dehydration, cardiac dysfunction and laboratory
abnormalities including lymphopenia, thrombocytopenia, elevated d-dimer and troponin. Class 3

270 represented a younger population with the milder form of MIS-C, and fewer organ systems 271 involved (hematological and renal). Class 2 represented an intermediate population with lower 272 illness severity than Class 1 but greater than Class 3, with 4-5 organ system involvement, including gastrointestinal (nausea, vomiting, abdominal pain, diarrhea), respiratory, 273 274 hematological and renal, and a lower incidence of cardiac dysfunction and abnormal troponin 275 levels, with a similar pattern to a subset of children with acute COVID-19. We also found a 276 higher proportion of patients with the more severe Class 1 phenotype seen earlier in the 277 pandemic, which decreased over time, with lower proportions of children with respiratory, 278 cardiac and hematological involvement and shock. These findings highlight the varied presentations of children with MIS-C, with wide illness spectrum, variable system involvement, 279 and cardiac involvement mostly confined to myocardial dysfunction rather than coronary artery 280 involvement. Our findings suggest that the degree of laboratory abnormalities rather than the 281 282 number of organ systems involved may be more useful indicators of illness severity, and may reflect differences in the degree of immune responses elicited. 283

284 Our multi-site study included children from diverse geographical regions across the United 285 States, and captured diagnoses, laboratory values, medications and procedures. Another 286 strength of our study is the use of LCA, which can be especially useful for identifying subgroups of individuals within a syndrome or condition who could benefit from a common intervention 287 based on their shared characteristics. LCA is also well-suited to describing different 288 manifestations of the novel syndrome of MIS-C. It divides patients into groups that might have 289 290 been previously unrecognized, based on shared characteristics, allowing for an unbiased determination of phenotypic manifestations.^{13, 17,18} Importantly, our LCA properly accounts for 291 292 between-site heterogeneity in patients by allowing different mixing proportions of subphenotypes, avoiding bias in estimated patient-level subphenotypes. Further, after 293 identification of subphenotypes using our LCA, we also characterized the differences in 294

variables in demographic, clinical conditions, and medications and labs, that were not used as
 manifest variables in our LCA. These results showed important differences in these variables
 across identified subphenotypes, which clinically validates our LCA results.

298 Our study is subject to several limitations. Given that inclusion of patients into our cohort was 299 based on a physician's diagnosis, we may have inadvertently included cases of suspected MIS-300 C who ultimately had other diagnoses, or children whose illnesses overlapped with Kawasaki disease. This risk for misclassification is low given that these diagnoses are assigned at 301 302 discharge. For example, we examined Kawasaki disease diagnoses in our analyses and the prevalence was low across the three latent classes, suggesting that these patients were 303 304 accurately classified. Next, our data captures hospitalizations at a PEDSnet site, and data from 305 earlier hospitalizations at other sites was not available. More subtle symptoms from MIS-C may 306 not have been captured in EHR data sources. Finally, the number of latent classes in LCA may 307 be difficult to determine, which is a well-known challenge in statistical inference, and may lead 308 to deceptive interpretations that the set of latent classes identified in an analysis represents the actual types of individuals in the population. To account for this, we have applied multiple model 309 selection criteria in selecting the number of subphenotypes. Further, we have conducted 310 311 sensitivity analyses on LCA using different numbers of subphenotypes. The final selected LCA model is a parsimonious model that describes distinct subphenotypes, which fits with clinical 312 observations and existing literature.¹⁹ 313

314 Our unsupervised learning methods using LCA identified a severe MIS-C subgroup with a

315 greater extent of left ventricular dysfunction leading to shock, and need for

316 vasopressors/inotropes. Abnormal cardiac strain has been shown to be associated with

317 increased odds of vasoactive support requirement, duration of vasoactive support, and ICU

length of stay.²⁰ An association has also been shown between the degree of inflammation and

319 cardiac injury severity, in particular CRP, troponin and NT-proBNP,²¹ as supported by our data.

320 Our data identified that those in the critically ill group were older and more likely to have an 321 underlying medical condition. In the literature, children affected by MIS-C tend to have fewer underlying medical conditions, with obesity a common diagnosis if chronic conditions were 322 present.²² Older age has been associated with worse outcomes from MIS-C,²³ but the 323 underlying immunologic mechanisms behind this observation have not yet been elucidated. 324 325 We identified a latent class subphenotype with 4-5 organ system involvement (Class 2), with overlapping features with children with acute COVID-19. A similar subphenotype has been 326 described in earlier studies of MIS-C.¹⁹ These and other studies indicate the clinical overlap in 327 some of the presentations of MIS-C and acute COVID-19. Further, the presence of abnormal 328 strain on echocardiogram has also been associated with greater number of organ systems 329 involved,²⁴ but our findings suggest that the number of organ systems involved does not 330 331 necessarily correlate with the degree of cardiac dysfunction and illness severity. Our third latent 332 class had a milder presentation, with shorter length of stay and a lower incidence of cardiac 333 involvement. This milder subgroup is an important cohort that warrants further exploration, as they may not require as aggressive treatment with immunomodulators to achieve the same 334 positive outcomes. 335

336 We evaluated the proportions of each subphenotype over time, and observed a trend towards 337 decreasing frequency of the severe MIS-C subphenotype. Earlier reports of MIS-C have indicated high levels of ICU support for patients with MIS-C. In a 2020 systematic review, 338 Ahmed et al. reported on 39 observational studies of MIS-C patients encompassing the period 339 January 1st, 2020 to July 25th, 2020. Out of 662 patients, 71% required admission to the 340 341 intensive care unit (ICU).²⁵ Further exploration of our cohort identified decreasing respiratory system involvement, cardiac involvement and shock, indicating decreased need for critical care 342 interventions. The reasons for this decreasing illness severity over time are likely multifactorial. 343 As clinicians' experience with this new condition matures, earlier identification and treatment 344

345 may lead to improved outcomes and decreased need for critical care. SARS-CoV-2 immunity in 346 children has been increasing through natural infection and vaccination, rendering less children susceptible to first-time encounters with SARS-CoV-2 infection triggering MIS-C. Another 347 hypothesis is that newer SARS-CoV-2 strains are less likely to stimulate the immune response 348 349 which causes multi-system inflammation. 350 In conclusion, we identified a set of subgroups of MIS-C with varying illness severity, sociodemographic characteristics and organ system involvement using latent class analyses. 351 352 These findings highlight the need for clinicians to recognize the varied clinical spectrum of presentations of MIS-C, and the importance of laboratory parameters to facilitate early 353 354 evaluation, diagnosis and treatment. 355 Declaration of Interests: Dr. Mejias reports funding from Janssen, Merck for research 356 support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr. Rao reports prior grant support from GSK and Biofire. Dr. Chen receives consulting support from 357 358 GSK. Dr. Jhaveri is a consultant for AstraZeneca, Segirus and Dynavax, and receives an editorial stipend from Elsevier. All other authors have no conflicts of interest to disclose. 359 360 **Role of funder/sponsor statement:** The funder had no role in the design and conduct 361 of the study; collection, management, analysis, and interpretation of the data; preparation, 362 review, or approval of the manuscript; and decision to submit the manuscript for publication. 363 Author contribution statement:

364 Drs Chen, Jing and Liu had full access to all of the data in the study and take responsibility for365 the integrity of the data and the accuracy of the data analysis.

366 Study concept and design: Rao, Chen, Jing, Liu, Forrest, Maltenfort, Lorman, Schuchard

- 367 Acquisition, analysis and interpretation of data: Rao, Jing, Liu, Lorman, Maltenfort, Schuchard,
- 368 Wu, Tong, Razzaghi, Forrest, Bailey
- 369 *Drafting of the manuscript:* Rao, Jing, Chen
- 370 Critical revision of the manuscript for important intellectual content: all authors
- 371 Statistical analyses: Jing, Liu, Chen, Wu, Tong
- 372 Obtained funding: Lee, Bailey, Forrest
- 373 Administrative, technical or material support: Rao, Chen, Bailey, Lee, Chen, Forrest
- 374 Study supervision: Rao, Chen, Forrest, Bailey, Forrest

375

Data sharing statement: The data is not publicly available due to privacy concerns. The

377 individual de-identified participant data will not be shared. The data that support the findings of

this study may be available through request and DUA process to the corresponding authors.

380 Table 1. Description of Study Cohort

	Characteristic	Number of patients (%) (N = 1186)		
Age at MIS-C	<1	30 (2.5%)		
diagnosis, years	1-4	259 (21.8%)		
	5-11	526 (44.4%)		
	12-15	244 (20.6%)		
	16-20	127 (10.7%)		
Sex	Female	463 (39.0%)		
	Male	723 (61.0%)		
Race/Ethnicity	Hispanic	253 (21.3%)		
	Non-Hispanic White	477(40.2%)		
	Non-Hispanic Black/African-American	291 (24.5%)		
	Non-Hispanic Asian/Pacific Islander	44 (3.7%)		
	Other/Unknown	69 (5.8%)		
	Multiple	52 (4.4%)		
Institution	A	193 (16.3%)		
	В	246(20.8%)		
	С	67(5.6%)		
	D	139 (11.7%)		
	E	189 (15.9%)		
	F	42 (3.5%)		
	G	197 (16.6%)		
	Н	113 (9.5%)		
PMCA index ^a	Non-complex chronic	806 (67.8%)		
	Chronic	64 (5.4%)		
	Complex-chronic	318 (26.8%)		
Obesity		134 (11.3%)		
Admitted to ICU		480 (40.5%)		
Died		11 (0.9%)		
Received		180 (15.2%)		
mechanical ventilation ^b				

381

- 382 Footnote: ^aPediatric Medical Complexity Algorithm (PMCA) classified children as complex-
- 383 chronic, chronic, or non-complex-chronic using an ordinal scale
- 384 ^binvasive or non-invasive
- 385 Abbreviations: MIS-C- multisystem inflammatory syndrome in children; ICU- intensive care unit

387 Figure 1. Heatmap of eight organ system variables used in latent class analyses with

388 three classes.

- **Figure legend**: The proportions of Class 1, 2, and 3 are 40.0%, 24.0%, and 36.0%,
- respectively. Each column represents a latent class, and each row represents a manifest
- 391 variable. The color of the boxes represents the prevalence of variables. The legend on the top
- right shows the scale of the colors. Red represents prevalence close to 100% and blue
- 393 represents prevalence close to 0%.

			Shock	0.8
			Dermatologic system involvement	0.6 0.4
			Gastroinstestinal system involvement	0.2
			Hematological system involvement	
			Neurologic system involvement	
			Renal system involvement	
			Respiratory system involvement	
			Cardiac involvement, coronary artery abnormalities only	
			Cardiac involvement with myocardial dysfunction only	
			Cardiac involvement with coronary artery abnormalities and myocardial dysfunction	1
Class 1	Class 2	Class 3		



Figure 2. Patient demographic characteristics in three latent classes.

Figure legend: Each line plot indicates the estimated prevalence and associated 95%

397 confidence interval of each variable in each class. Class 1 is represented as a blue square,

Class 2 as a red circle, and Class 3 as a purple diamond. The I-squared statistic measures the

- 399 heterogeneity among the latent classes. P-values are obtained through Cochran's Q test, where
- 400 the null hypothesis is no between-class heterogeneity. A large I-squared and a small p-squared
- 401 indicate a large between-class heterogeneity. A) I-squared, p-value, estimated prevalence, and

- its 95% confidence interval for discrete variables. B) I-squared, p-value, estimated mean, 402
- standard deviation, median and interquartile range for continuous variables. 403



Class 1 Class 2 Class 3

404

В

	Mean (SD)			Median (IQR)				p-
	Class 1	Class 2	Class 3	Class 1	Class 2	Class 3	I-squared	value
Age in years	10.2	8.5	7.3	10.1	8.2	6.3	97.6%	<0.01
	(4.5)	(4.7)	(4.7)	(6.9, 13.6)	(4.5, 12.0)	(3.0, 11.2)		
Inpatient days	8.6	5.7	4.7	6	5	4	93.3%	<0.01
	(13.7)	(8.7)	(6.9)	(5, 9)	(4, 6)	(3, 5.2)		
Days in ICU	3.6	0.7	0.8	3	0	0	98.0%	<0.01
	(5.8)	(3.0)	(2.1)	(0, 4)	(0, 0)	(0, 0)		
Highest CRP (mg/dL)	20.3	14.1	12.3	20.0	13.4	9	78.4%	<0.01
	(10.9)	(10.0)	(9.4)	(11.1, 26.6)	(6.0, 21.6)	(5.1, 19.2)		
Highest troponin (ng/ml)	1.3	0.1	0.1	0.01	0.14	0.01	98.6%	<0.01
	(8.4)	(0.7)	(0.8)	(0, 0.05)	(0.02, 0.36)	(0, 0.05)		

406	Footnote: SARS-CoV-2 infection includes positive PCR, antigen or serology; SARS-CoV-2
407	exposure indicates that patient had a history of exposure to a contact with known SARS-CoV-2
408	based on ICD-10 codes; age group is presented in years; Pediatric Medical Complexity
409	Algorithm (PMCA) classified children as complex-chronic (2), chronic (1), or non-complex-
410	chronic (0).
411	Abbreviations: SDstandard deviation; IQR—interquartile range; PMCA Pediatric Medical
412	Complexity Algorithm; PI- Pacific Islander; AA- African American; SARS-CoV-2severe acute
413	respiratory syndrome coronavirus; ICU- intensive care unit; CRP- C-reactive protein
414	
415	Figure 3. Heatmap of patient characteristics of conditions, laboratory results and
416	medication in three latent classes.
417	Figure legend: Each column represents a latent class, and each row represents a variable. The
418	color of the boxes represents the estimated prevalence of variables. The legend on the top right
419	shows the scale of the colors. Red represents prevalence close to 100% and blue represents
420	prevalence close to 0%. The conditions and laboratory results are ordered based on organ
421	systems.
422	
423	
424	
425	
426	
720	
427	

428						0.8
				Heart failure		0.0
				Myocarditis		
120				Arrhythmias	Cardiac	0.6
423				Hypotension		
				Pericarditis		0.4
				Cardiomyopathy		
430				Coronary artery abnormalities		
				Serum/plasma Troponin > 0.1 ng/mL		0.2
				Skin rashes		
/121				Skin signs and symptoms	Skin	0
451				Conjunctivitis		
				Abdominal pain		
				Nausea and vomiting		
432				Diarrhea	Gastrointestinal	
				Intestinal obstruction and ileus		
				Gastroenteritis		
100				Thrombophlebitis and thromboembo	lism	
455				Aplastic anemia		
				1 ymphocytes < 1.000/microliter	Hematological	
				Platelets < 150 000/microliter		
434				Plasma/serum D_dimer $> 2 \text{ md/dl}$		
					Nourological	
435				Delivium	Neurological	
				Delinum Ensenholonothu		
				Encephalopathy		
				Nervous system signs and symptoms	s	
436				Acute kidney injury	Renal	
				Fluid and electrolyte disturbance		
				Creatinine, age < 3yr, > 0.7 mg/dL O	R age 3yr, > 1.0 mg/dL	
/137				Dialysis		
437				Pneumonia		
				Bronchiolitis	Respiratory	
				Bronchitis		
438				Cough		
				Cardiorespiratory signs and sympton	ns	
				Chest pain		
139				Acute respiratory distress syndrome		
433				Respiratory failure		
				Pleurisy pleural effusion and pulmon	ary collapse	
				Ventilation		
440				Kawasaki disease	Others	
				Ace inhibitors		
				Antiarrhythmics class I and III		
441				Direct acting antivirals	Medication	
				Beta blockers		
				Cough suppressants		
				Immunomodulators		
442				Oral steroids		
				Antimigraine preparations		
				Antiinflammatory and antirheumatic	products, non steroids	
443				Antihistamines for systemic use		
				Systemic steroids		
				Vasopressors		
444	Class 1	Class 2	Class 3			

448 Figure 4. Proportions of three MIS-C classes over time

- 449 **Figure legend**: Each line represents the proportion of the three classes over 3-month periods.
- 450 The proportions of the classes are calculated using the average of the posterior class
- 451 membership probabilities of the patients who are diagnosed in the given time window. The
- 452 calendar time is segmented quarterly. Time intervals with small sample sizes are combined and
- 453 labeled by a star. A) Proportions of the three subphenotypes across time. Each line represents
- 454 a subphenotype. **B)** Histogram of the number of patients in each time window, including timing
- 455 of predominant SARS-CoV-2 variant activity.



457 References

458	1 Verdoni I. Mazza A. Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian
459	enicentre of the SARS-CoV-2 enidemic: an observational cohort study <i>Lancet</i> Jun 6
460	2020:395(10239):1771-1778 doi:10.1016/S0140-6736(20)31103-X
461	2 Rinhagen S. Gomez X. Gonzalez-Martinez C. Wilkinson N. Theocharis P. Hyperinflammatory
462	shock in children during COVID-19 nandemic <i>Lancet</i> May 23 2020:395(10237):1607-1608
462	doi:10.1016/S0140-6736(20)31094-1
405	2 Contars for Disease Control and Provention, Multisystem Inflammatory Syndrome in Children
404	(MIS C) Associated with Coronavirus Disease 2010 (COV/ID 10) Associated May 20, 2022
405	(WIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Accessed Way 20, 2022,
400	<u>Mups://emergency.cuc.gov/nan/2020/nan/00432.dsp</u>
407	4. Rausink A, Gupta S, Soou W, Sharria S, Verna S. A Systematic Review of Multisystem
408	Initial matory syndrome in children Associated with SARS-COV-2 mection. Pediatr inject Dis J. Nov
469	2020;39(11):e340-e346. doi:10.1097/INF.000000000000002888
470	5. Dufort EIVI, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New
4/1	York State. N Engl J Med. Jul 23 2020;383(4):347-358. doi:10.1056/NEJM0a2021756
472	6. Patel JM. Multisystem Inflammatory Syndrome in Children (MIS-C). <i>Curr Allergy Asthma Rep</i> .
4/3	May 2022;22(5):53-60. doi:10.100//s11882-022-01031-4
474	7. Center for Disease Control and Prevention. COVID Data Tracker. Health Department-Reported
475	Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. Accessed June
476	20, 2022, https://www.cdc.gov/mis-c/cases
477	8. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children
478	and Adolescents. <i>N Engl J Med</i> . Jul 23 2020;383(4):334-346. doi:10.1056/NEJMoa2021680
479	9. Rao S LG, Razzaghi H, Lorman V, Mejias A, Pajor NM, Thacker D, Webb R, Dickinson K, Bailey LC,
480	Jhaveri R, Christakis DA, Bennett TD, Chen Y, Forrest CB. Clinical features and burden of post-acute
481	sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study
482	from the RECOVER program. JAMA Pediatrics. 2022; in press
483	10. Forrest CB, Margolis PA, Bailey LC, et al. PEDSnet: a National Pediatric Learning Health System. J
484	Am Med Inform Assoc. Jul-Aug 2014;21(4):602-6. doi:10.1136/amiajnl-2014-002743
485	11. Forrest CB, Margolis P, Seid M, Colletti RB. PEDSnet: how a prototype pediatric learning health
486	system is being expanded into a national network. <i>Health Aff (Millwood)</i> . Jul 2014;33(7):1171-7.
487	doi:10.1377/hlthaff.2014.0127
488	12. Melton B, Liang KY, Pulver AE. Extended latent class approach to the study of familial/sporadic
489	forms of a disease: its application to the study of the heterogeneity of schizophrenia. Genet Epidemiol.
490	1994;11(4):311-27. doi:10.1002/gepi.1370110402
491	13. Bandeen-roche K MD, Zeger SL, Rathouz PJ. Latent Variable Regression for Multiple
492	Discrete Outcomes. Journal of the American Statistical Association. 1997;92(440):1375-1386.
493	14. Linzer DA LJ. poLCA: an R Package for Polytomous Variable Latent Class Analysis. <i>Journal of</i>
494	Statistical Software. 2011;42(10):1-29.
495	15. poLCA: Polytomous Variable Latent Class Analysis." R package version 1.4
496	http://dlinzer.github.com/poLCA.
497	16. Simon TD, Cawthon ML, Popalisky J, Mangione-Smith R, Center of Excellence on Quality of Care
498	Measures for Children with Complex N. Development and Validation of the Pediatric Medical Complexity
499	Algorithm (PMCA) Version 2.0. <i>Hosp Pediatr</i> . Jul 2017;7(7):373-377. doi:10.1542/hpeds.2016-0173
500	17. !!! INVALID CITATION !!! 15-18;
501	18. Linzer DA LJ. poLCA: An R Package for Polytomous Variable Latent Class Analysis. <i>Journal of</i>

502 *Statistical Software*. 2011;41(10):1-29.

503 19. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-Associated Multisystem Inflammatory
504 Syndrome in Children - United States, March-July 2020. *MMWR Morb Mortal Wkly Rep*. Aug 14
505 2020;69(32):1074-1080. doi:10.15585/mmwr.mm6932e2

506 20. Basu S, Kim EJ, Sharron MP, et al. Strain Echocardiography and Myocardial Dysfunction in

507 Critically III Children With Multisystem Inflammatory Syndrome Unrecognized by Conventional

508 Echocardiography: A Retrospective Cohort Analysis. *Pediatr Crit Care Med*. Mar 1 2022;23(3):e145-e152. 509 doi:10.1097/PCC.00000000002850

510 21. Farooqi KM, Chan A, Weller RJ, et al. Longitudinal Outcomes for Multisystem Inflammatory

511 Syndrome in Children. *Pediatrics*. Aug 2021;148(2)doi:10.1542/peds.2021-051155

512 22. Chow EJ, Englund JA. Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.

513 Infect Dis Clin North Am. Jun 2022;36(2):435-479. doi:10.1016/j.idc.2022.01.005

514 23. Merckx J, Cooke S, El Tal T, et al. Predictors of severe illness in children with multisystem

inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study. *CMAJ*. Apr 11
 2022;194(14):E513-E523. doi:10.1503/cmaj.210873

517 24. Fremed MA, Farooqi KM. Longitudinal Outcomes and Monitoring of Patients With Multisystem

518 Inflammatory Syndrome in Children. Front Pediatr. 2022;10:820229. doi:10.3389/fped.2022.820229

519 25. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: A

520 systematic review. *EClinicalMedicine*. Sep 2020;26:100527. doi:10.1016/j.eclinm.2020.100527